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ABSTRACT 
 
Lafora Disease (LD, OMIM 254780, ORPHA501) is a devastating neurodegenerative 
disorder characterized by the presence of glycogen-like intracellular inclusions called 
Lafora bodies and caused, in most cases, by mutations in either EPM2A or EPM2B 
genes, encoding respectively laforin, a phosphatase with dual specificity that is involved 
in the dephosphorylation of glycogen, and malin, an E3-ubiquitin ligase involved in the 
polyubiquitination of proteins related with glycogen metabolism. Thus, it has been 
reported that laforin and malin form a functional complex that acts as a key regulator of 
glycogen metabolism and that also plays a crucial role in protein homeostasis 
(proteostasis). In relationship with this last function, it has been shown that cells are 
more sensitive to ER-stress and show defects in proteasome and autophagy activities in 
the absence of a functional laforin-malin complex. More recently, we have 
demonstrated that oxidative stress accompanies these proteostasis defects and that 
various LD models show an increase in reactive oxygen species and oxidative stress 
products together with a dysregulated antioxidant enzyme expression and activity. In 
this review we discuss possible connections between the multiple defects in protein 
homeostasis present in LD with oxidative stress. 
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1. Pathophysiology of Lafora disease 
Lafora disease (LD, OMIM 254780, ORPHA501) is a rare, fatal, autosomal 
recessive form of progressive myoclonus epilepsy (PME) that occurs worldwide, but is 
relatively more frequent in Mediterranean countries. The term PME describes a group 
of disorders characterized by the occurrence of focal and generalized seizures, 
myoclonus, and progressive neurological deterioration, typically with cerebellar signs 
and dementia [1, 2]. The most common causes of PME are Unverricht-Lundborg 
Disease (ULD; due to mutations in the CSTB gene encoding cystatin B, a lysosomal 
cysteine protease inhibitor), myoclonic epilepsy with ragged red fibbers (MERRF; 
mainly due to mutations in the mitochondrial gene MTTK encoding the tRNA
Lys
), 
neuronal ceroid lipofuscinoses (NCL, a collection of inherited diseases due to mutations 
in more than ten different CLN genes), dentatorubropallidoluysian atrophy (DRPLA; 
due to an expansion of a CAG repeat in the DRPLA gene encoding atrophin-1), 
sialidosis (a lysosomal storage disease due mutations in the NEU1 gene encoding the 
lysosomal enzyme α-N-acetyl-neuraminidase) and Lafora disease (LD; see below) [1, 
2]. 
Lafora disease is unique among the PMEs due to the rapid neurological 
deterioration of the patients and the appearance of insoluble glycogen-like intracellular 
inclusions named Lafora bodies (LBs) in brain and other tissues [3, 4] (Table 1). LD 
initially manifests during adolescence with generalized tonic-clonic seizures, 
myoclonus, absences, drop attacks or visual hallucinations. As the disease proceeds, a 
rapidly progressive dementia with apraxia, aphasia, and visual loss ensues leading 
patients to a vegetative state and death, usually within the first decade from the onset of 
the first symptoms [5-7]. Mutations have been identified in two genes, EPM2A [8, 9] 
and EPM2B [10], although there is evidence for a third locus [11]. EPM2A, located on 
chromosome 6q24 [12], is mutated in approximately 60% of LD cases. EPM2A encodes 
laforin, a dual-specificity phosphatase of 331 amino acids with a functional 
carbohydrate binding domain at the N-terminus [13, 14]. A second gene, EPM2B, 
located on chromosome 6p22.3, was found to be mutated in 20-30% of LD patients [10, 
15]. EPM2B encodes malin, an E3 ubiquitin ligase of 395 amino acids with a RING 
finger domain at the N-terminus and six NHL domains in the C-terminal region [16] 
[17]. More than 60 different mutations have been reported in EPM2A and EPM2B genes 
(see http://projects.tcag.ca/lafora, for a comprehensive relation of the reported 
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pathogenic mutations in both genes). They include missense point mutations, premature 
termination codons (PTCs, i.e. stop codons) truncating the majority of the 
corresponding protein, frameshift and deletion mutations. The final outcome of these 
mutations ranges from the formation of catalytically inactive proteins to the absence of 
the corresponding protein. To study the pathophysiology of LD, mouse models lacking 
functional EPM2A or EPM2B genes have been produced [either by deletion of exon 4 in 
the case of EPM2A (a four exon containing gene) [18] or by deletion of the whole gene 
in the case of EPM2B (a mono-exonic gene) [19]]. They both recapitulate the Lafora 
disease phenotype: they accumulate polyglucosan inclusions, show signs of 
neurodegeneration and have a dysregulation of protein homeostasis (proteostasis). 
 
2. Laforin and malin, new players in the regulation of glycogen synthesis. 
As indicated above, a hallmark of LD is the accumulation of Lafora bodies 
(LBs) [3, 4]. They are abnormal, poorly branched intracellular glucose polymers 
composed, like normal glycogen, of glucose residues joined by α-1,4-glycosidic 
linkages with α-1,6-glycosidic branches [20]. However, in LBs, the glycosidic branches 
in these glucose polymers occur less frequently than in glycogen and contain higher 
levels of phosphate. These two properties (less branching and higher phosphate content) 
make LBs largely insoluble [21-23]. Recent work has revealed that LBs appear as a 
consequence of dysregulation of glycogen synthesis due to the absence of either laforin 
or malin, pointing to a key role of these proteins in glycogen homeostasis [see [24], 
[25], for review]. Although all cells in LD patients can develop LBs, neurons are 
especially sensitive to energy perturbations and, for this reason, the accumulation of 
LBs may be more detrimental in these cells, triggering neuronal death [26-28]. For a 
long time, it was assumed that the role glycogen played in the brain was only as an 
emergency energy supply. However, recent data suggest that glycogen has a more 
dynamic role in brain metabolism [29-31]. In fact, it has been reported that glycogen 
breakdown in astrocytes is required for the reuptake of extracellular K
+
, a critical 
process for neuronal activity [29, 32]. In addition, it has been reported that glycogen 
plays a crucial role in learning and long-term memory formation [33]. It has also been 
assumed that astrocytes were the only neural cells that synthesize and degrade glycogen, 
but it has been recently demonstrated that neurons express glycogen synthase and 
glycogen phosphorylase and accumulate low levels of glycogen that are essential to 
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resist hypoxic conditions [34]. Thus, the general view of the importance of glycogen in 
neural physiology is changing.  
Glycogen synthesis in neurons must be tightly controlled, since over-
accumulation of this polysaccharide is detrimental for these cells [26-28]. Interestingly 
enough, during human aging neurons accumulate glycogen-like granules named 
“corpora amylacea” (CA), which both morphologically and in composition resemble 
LBs. Like LBs (see below), CA contain low branched polyglucosans and proteins 
(ubiquitinated proteins, advanced glycation-end products, chaperones). This raises the 
possibility that neuronal glycogen accumulation contributes to physiological aging as a 
key factor regulating age-related neurological decline in humans. If this neuronal 
glycogen accumulation is accelerated, as in LD, then a more pathological situation 
ensues [35]. 
The role that laforin and malin play in the regulation of glycogen synthesis is 
twofold. First, it has been described that laforin acts as a phosphatase of complex 
carbohydrates, being this function necessary for the maintenance of normal glycogen 
homeostasis [21, 36]. In the absence of laforin, glycogen becomes highly 
phosphorylated and less branched, decreasing the solubility of this polysaccharide [21-
23] and leading to the formation of LBs (Figure 1). Second, it is known that laforin 
interacts physically with malin, forming a functional complex [16, 17, 37]. In this 
complex, laforin would recruit specific substrates to be ubiquitinated by malin (see 
below, section 3.2). Some of these substrates are involved in the regulation of glycogen 
biosynthesis, such as the muscle isoform of glycogen synthase (MGS) [26], the 
glycogen debranching enzyme (AGL) [38], and the R5/PTG and R6 glycogen targeting 
subunits of type 1 protein phosphatase (PP1) [26, 37, 39, 40] (Figure 1). Most 
importantly, the formation of the laforin-malin complex is a regulated process in which 
AMP-activated protein kinase (AMPK) plays a critical role. The involvement of AMPK 
in the regulation of the laforin-malin complex adds a metabolic component to our 
understanding of the pathogenesis of LD [37]. The laforin/malin complex thus appears 
to be part of a multiprotein complex that is involved in the regulation of glycogen 
synthesis. For this reason, the accumulation of LBs has led some authors to consider LD 
as a new member of the family of glycogen storage diseases, being the 
formation/accumulation of LBs the signal that triggers LD. Supporting this hypothesis 
is the fact that the elimination of the capacity of the cells to synthesize glycogen, either 
by depleting MGS or the protein targeting to glycogen (PTG) in animal models of LD, 
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not only results in the elimination of the accumulation of LBs, but also in the 
amelioration of the neuropathological symptoms [28, 41, 42]. These results have led 
those authors to suggest the use of MGS inhibitors as a putative strategy to treat LD.  
 
3. Lafora disease and cellular proteostasis. 
Protein homeostasis (proteostasis) is achieved by the coordinated action of an 
efficient folding and transport of newly synthesized proteins and an active quality 
control with degradative mechanisms reducing the load of unfolded/misfolded proteins, 
to prevent thereby abnormal protein aggregation [43]. When the folding capacity is 
saturated, unfolded/misfolded proteins are usually tagged with ubiquitin moieties to 
target them for proteasome and/or lysosomal degradation. If these protein clearance 
mechanisms are not efficient, then unfolded/misfolded proteins accumulate and tend to 
form oligomeric structures. Thus, the presence of protein aggregates is an indication of 
an altered proteostasis [43]. 
LBs contain, in addition to insoluble glycogen-like polysaccharides 
(polyglucosans), ubiquitinated proteins, advanced glycation-end products, chaperones, 
autophagy components and proteasome subunits [35, 44] (Table 1). Probably, 
polyglucosan fibers start to accumulate in the initial steps of LB formation due to a 
dysregulation in the synthesis of glycogen. These insoluble polyglucosans would act as 
a seed to attract components of the protein clearance machinery (ubiquitin proteasome 
system, autophagy, etc.), which will get trapped into the insoluble inclusions and will 
become unable to function properly. Therefore, LD can be considered as another 
example of proteostasis dysfunction, being then linked to the group of 
neurodegenerative proteinopathies. In fact, recent work has demonstrated that neuronal 
death in LD could be influenced not only by the accumulation of LBs, but also by an 
impairment in the proteostasis mechanisms (Figure 1), similarly to what it has been 
described in more frequent neurodegenerative diseases (i.e., Parkinson´s, Alzheimer´s, 
etc.). 
In this section we will review the relationships between LD, ER-stress, protein 
clearance (proteasome and autophagy) and oxidative stress. 
 
3.1. Laforin, malin, and endoplasmic reticulum stress. 
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Endoplasmic reticulum (ER) is the sub-cellular compartment for the synthesis 
and folding of all ER, Golgi, lysosomal, secreted and plasma membrane proteins. ER 
function is highly sensitive to stresses that perturb cellular energy levels, red-ox status 
or Ca
++
 concentration. Such stresses reduce the folding capacity of the ER, which 
results in the accumulation and aggregation of unfolded proteins in the lumen. These 
events trigger a signal responsible for the activation of the unfolded protein response 
(UPR) that restores the ER function. In addition, unfolded proteins are retrotranslocated 
to the cytosol, polyubiquitinated and degraded by proteasomes in the ER-associated 
degradation pathway. The UPR pathway is characterized by the activation of two ER-
resident kinases (PKR-like ER kinase, PERK; and the inositol-requiring protein 1, 
IRE1) and the translocation to the Golgi apparatus and subsequent cleavage of ATF6, a 
transmembrane ER-resident protein with a cytosolic domain with transcriptional 
activity. These components induce signaling cascades that lead to the overexpression of 
characteristic UPR-mediators, such as the heat shock protein BIP/Grp78, the protein 
disulphide isomerase (PDI), the transcriptional factor CHOP (a member of the C/EBP 
family of bZIP transcription factors that induces apoptosis) and the phosphorylated form 
of the eukaryotic initiation factor 2 alpha (p-EIF2α), among others. However, if 
conditions of ER-stress persist, these mechanisms of adaptation are insufficient to 
handle the unfolded protein load and cells undergo apoptosis (see [45], [46], [47], [48], 
[43], for review). ER-stress conditions are also associated to the generation of 
intracellular reactive oxygen species (ROS) from ER. Electron transport during 
disulphide-bound formation is driven by protein disulphide isomerase (PDI) and ER-
oxidoreductin 1 (ERO1), who uses a flavin-dependent reaction to transfer electrons 
from PDI to molecular oxygen. Under conditions of ER-stress, ERO1 is upregulated, 
leading to the accumulation of ROS [49]. ER-derived ROS production contributes to the 
establishment of a cellular oxidative stress status that is detrimental to the cell. 
Several labs have reported that the laforin-malin complex plays a role in 
protecting cells from ER-stress conditions [44, 50-52]. For instance, in cell culture 
models depleted of malin or laforin, there is an increased ER-stress response that 
eventually leads to decreased proteasome function and increased apoptosis, which could 
be important factors in the development of LD [50, 51] (Table 1). This higher 
sensitivity of laforin/malin deficient cells to conditions of ER-stress may predispose 
them to the development of oxidative stress. In addition, since ER-stress conditions are 
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pro-inflammatory, as they activate the JNK and IKK pathways [53], it is quite possible 
that neuroinflammation could be a new trait in the physiopathology of LD. 
3.2. Proteolytic impairment in Lafora disease 
As indicated above, it was early described that besides glycogen-like polymers, 
LBs also contain about 6% protein [4, 54] and stain positive with anti-ubiquitin 
antibodies [18]. These observations suggested the presence of a certain amount of 
misfolded proteins in LBs and, thus, it was proposed that LD could be a disorder of 
protein clearance [55]. This proposal has been further supported by the presence in LBs 
of chaperones and proteasome subunits [35, 44], an observation that resembles similar 
situations in many proteinopathies in which the proteolytic mechanisms of the cells are 
impaired. Therefore, like in these pathologies, it is possible that in LD the protein 
folding capacity is exceeded, and that the intracellular protein degradation systems are 
also altered, resulting in the accumulation in LBs of chaperones, aggregate-prone 
proteins, free ubiquitin, ubiquitinated proteins, proteasome components and probably 
ATGs (autophagy-related gene products), among other proteins related with the 
proteostasis mechanisms. In fact, we have recently described a reduction in the total 
proteolytic capacity present in mouse embryonic fibroblasts from Epm2a-/- and Epm2b-
/- mice, and also in fibroblasts from patients suffering from EPM2A and EPM2B 
mutations [19, 56, 57] (Table 1). 
In mammalian cells the ubiquitin proteasome system and autophagy (Figure 2) 
are the major protein degradative systems [58] and an interconnection between both has 
been outlined [59]. In mammalian cells proteasomes and lysosomes are equally 
important in the degradation of short- and long-lived proteins, but their relative 
importance varies with the cell type, its metabolic situation, and the specific protein to 
be degraded [60, 61]. Our own results indicate that the reduction in the total proteolytic 
capacity present in LD cellular models described above, affects both proteasome and 
lysosome activities [19, 56, 57]. In the following sections we will describe the impact of 
the absence of laforin and malin on the different proteolytic systems. 
3.2.1. Alterations of the ubiquitin-proteasome system (UPS) in Lafora disease 
The UPS [62] acts in two parts, both consuming ATP (see Figure 2A): the 
polyubiquitination of protein substrates and their degradation by the downstream 26S or 
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30S proteasomes, composed by the 20S catalytic core and, respectively, one or two 19S 
regulatory particles. Canonical ubiquitination, which is a reversible process, involves 
three steps: i) activation of ubiquitin by a process that requires ATP and the E1 
(ubiquitin-activating) enzyme, ii) transfer of the ubiquitin from the E1 to an E2 
(ubiquitin-conjugating) enzyme, and iii) direct or indirect transfer of ubiquitin to an 
inner Lys of a specific protein substrate recognized by an E3 (ubiquitin-ligase) enzyme. 
Combinations of the large number of E2 enzymes and especially of E3 enzymes ensure 
the specificity of the whole process. The ubiquitination of a substrate protein can be 
sequentially repeated to generate a polyubiquitin chain, which is usually composed of 
four or more ubiquitin units attached to the substrate protein. In most proteasome 
substrates the ubiquitin moieties of the polyubiquitin chain are attached to each other by 
their Lys48, but there are also numerous exceptions. Since ubiquitin contains seven 
different Lys residues, a high variety of ubiquitin linkages and of polyubiquitin chains 
exists. This diversity may serve to regulate other cell functions different from 
proteasomal degradation, as it is also the case of monoubiquitination, but the important 
point here is that most proteins marked with Lys48-linked polyubiquitin chains (but also 
with some of the other linkages) are recognized, deubiquitinated to generate free 
ubiquitin and degraded in the 20S proteasome by processes that also consume ATP.  
The fact that EPM2B encodes a protein, malin, which contained six NHL 
domains implicated in protein-protein interactions and an N-terminal RING-finger 
domain, immediately suggested a role of the protein as an E3-ubiquitin ligase [10], most 
probably involved in the degradation by the UPS of some proteins that produce the 
accumulation of LBs. Later, it was experimentally shown that malin interacts with 
laforin and catalyzes its polyubiquitination and degradation, at least under in vitro 
conditions [17, 63]. This brought into relation two apparently different proteins, an E3 
ubiquitin ligase (malin) and a protein containing a dual specificity phosphatase domain 
(laforin), but whose defects produce the same disease. However, if laforin is a malin 
substrate and at the same time plays the main positive role to prevent the pathology, for 
example as a glucan phosphatase in the dephosphorylation of glycogen to avoid the 
formation of polyglucosans [21, 64], it could be expected that defects in malin would 
elevate the levels and, thus, the activity of laforin. This fact would be difficult to 
reconcile with data showing that defects in malin or in laforin produce a similar 
histological and neurological phenotype. The difficulty could be circumvented if the 
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elevated levels of laforin were not active in the absence of malin and/or if the excess of 
laforin becomes sequestered in specific compartments such as LBs [65]. However, even 
so, the role of malin in relationship with the glucan phosphatase activity of laforin 
would still require a different explanation from simply polyubiquitinating laforin for 
proteasomal degradation. 
In this regard, it was crucial the discovery that laforin also interacts with proteins 
involved in glycogen biosynthesis [66], such as MGS and PTG, which brings protein 
phosphatase 1 to MGS. In fact, MGS [26], AGL [38] and PTG [26, 37, 39] were 
identified as substrates of the malin-laforin system. Therefore, it could be possible that 
it is the ubiquitin ligase malin who plays the main role in the molecular mechanisms 
that prevent LD, by facilitating the modification of enzymes involved in the synthesis of 
glycogen in neurons, thus avoiding an excessive accumulation of this polysaccharide 
that would be toxic in these cells. In this setting, laforin could act as an ancillary protein 
placing specific substrates involved in glycogen metabolism in the proximity of malin 
to be polyubiquitinated and possibly degraded by the proteasomes. However, later 
studies from different laboratories found that the levels of PTG, MGS or AGL were not 
altered in malin- or laforin-deficient mice [22, 67], making unlikely this possibility to 
explain the molecular basis of LD. Even the possibility that laforin is an in vivo malin 
substrate has been also recently questioned (see e.g. [68]). Therefore, it remains to 
clearly identify all substrates of malin under in vivo conditions and this would be 
probably very important for a better understanding of the molecular basis of LD and its 
associated accumulation of LBs. 
Various reports indicate that the laforin-malin complex promotes the formation 
of Lys63-linked ubiquitin chains in different substrates [40, 69, 70] and although no 
information is known yet about the E2-conjugating enzyme that participates in this 
reaction in vivo, it has been described that malin can promote an in vitro efficient 
ubiquitination when associated with the E2-conjugating enzymes UbcH2, UbcH5 and 
UbcH6 [17, 37]. Also, it has been proposed that the U-box co-chaperone CHIP 
stabilizes malin [44]. Since CHIP may interact with the E2 UbcH13/Uev1a, a 
heterodimeric E2 enzyme that exclusively forms K63-linked ubiquitin chains [71, 72], it 
could be possible that laforin and malin could form a macrocomplex with CHIP and 
UbcH13/Uev1a, which would be responsible for the K63-linked ubiquitination of 
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specific substrates. Alternatively, laforin and malin could interact directly with 
UbcH13/Uev1a. 
The accumulation of ubiquitinated and misfolded proteins in LBs could indicate 
a failure of the UPS to get rid of them in LD, as it occurs in many other 
neurodegenerative diseases. In fact, different studies with various LD models have 
illustrated the existence of defects in the ubiquitin-proteasome system [51, 57, 63, 73]. 
Although no UPS defects were observed in brain from laforin- or malin-deficient mice 
[19], these defects were observed by others using laforin- or malin-deficient mouse 
embryo fibroblasts under stress conditions [68]. Therefore, it is possible that in laforin- 
or malin-deficient cells, stress conditions overwhelm the activities of the chaperone 
machinery and the UPS, causing misfolding and ubiquitination of proteins that 
aggregate in LBs, and that this in turn reduces the activity of the UPS, causing further 
alterations that would be especially deleterious for sensitive cells, like neurons. These 
alterations could contribute to the pathology in LD, but because of the above mentioned 
proteasome-autophagy interconnection, they would be even worse if the other major 
intracellular protein degradation system, autophagy, is also altered. This possibility is 
discussed below. 
3.2.2.- Alterations of lysosomes in LD 
The lysosome is the final destination for endocytic, autophagic, and secretory 
molecules targeted for destruction by a variety of acid hydrolases, including numerous 
peptidases called cathepsins. Lysosomes degrade cellular proteins by different 
mechanisms being endocytosis, crinophagy and the various autophagies the best 
established of them [58]. Endocytosis (also called heterophagy) is the degradative route 
to lysosomes, via early and late endosomes, that is followed by extracellular material 
and also by certain plasma membrane proteins that, unlike the low density lipoprotein 
receptor and the transferrin receptor for example, do not recycle back to the plasma 
membrane for reuse. By crinophagy, secretory proteins are degraded by lysosomes 
when their demands outside the cell decrease and this occurs by fusion of the secretory 
granules with lysosomes or with late endosomes instead of with the plasma membrane. 
Finally, the main lysosomal mechanism for intracellular proteolysis is autophagy, a 
general term with at least three different forms of “self-eating”: macroautophagy, 
microautophagy, and chaperone-mediated autophagy (see Figure 2B). By 
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microautophagy specific cell areas enter into lysosomes by various modifications of the 
lysosomal membrane. In chaperone-mediated autophagy, specific proteins containing a 
KFERQ-like signal enter lysosomes through a receptor (LAMP2a) at the lysosomal 
membrane by a complicated process that requires ATP and cytosolic and lysosomal 
chaperones. Macroautophagy is by far the most important and best known lysosomal 
degradative route and, therefore, it is frequently and simply called autophagy, as we will 
do hereafter. It involves the sequestration by a segregating structure, called phagophore, 
of large areas of cytoplasm, typically including whole organelles, to make up an 
autophagosome. These pre-lysosomes fuse then with endosomes and lysosomes to form 
an amphilysosome or an autolysosome in which the sequestered cytoplasmic content is 
quickly degraded by the high concentration of acid hydrolases.  
Based on the above mentioned dysfunction of the UPS in LD, it was possible 
that lysosomes in general and autophagy in particular, could be also affected in the 
disease. The main reasons to test this possibility were the following. First, autophagy 
complements the UPS for the degradation of polyubiquitinated proteins and can 
compensate defects on it. This is especially due to the fact that large autophagosomes 
can sequester material that cannot enter the narrow proteasome channel, such as 
aggregated proteins and altered mitochondria. Therefore, autophagy is more effective 
than proteasomes to eliminate aggregated or altered material of a certain size after 
delivery to lysosomes. Second, autophagy can also degrade polyubiquitinated proteins 
and it has been found that the laforin-malin complex promotes, at least in some of its 
substrates, the formation of K63-linked polyubiquitin chains [69]. These polyubiquitin 
linkages can target these substrates for degradation in lysosomes (see [58] for a review) 
and in relationship to LD, this was the case for the protein phosphatase 1 regulatory 
subunit R6 [40]. Finally and more important, lysosomes represent a well-established 
route in the degradation of glycogen, as exemplified by the accumulation of glycogen in 
lysosomes in Pompe’s disease due to a deficiency in the lysosomal enzyme acid maltase 
[74]. Therefore it seems possible that the accumulation of polyglucosans in LD derives 
from a defect in autophagy. 
In fact, impairment in autophagy in Epm2a
-/-
 and Epm2b
-/-
 mice models of LD 
was described, leading to decreased levels of LC3-II, a marker of autophagy,  decreased 
degradation of long-lived proteins and increased levels of the autophagic component 
p62 [19, 56]. Later, different laboratories [28, 68, 75, 76] also noticed a similar 
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impairment in autophagy in various LD models (Table 1). This defect probably occurs 
through the mammalian target of rapamycin kinase (mTOR) pathway-dependent 
inhibition of autophagosome formation [68, 77], although other unidentified signalling 
pathways to autophagy may be also implicated in brain [78]. Since autophagy degrades 
practically all macromolecules and organelles in the cell, additional consequences of the 
autophagy defects in LD should occur, besides glycogen accumulation. In particular, the 
autophagy defect should produce, in LD, an accumulation of undegraded proteins and 
lipids and of defective mitochondria, and since these organelles are the primary source 
of reactive oxygen species, increased levels of these molecules should occur in LD. In 
fact, recent data obtained by the authors of this review have shown alterations in 
mitochondria and increased levels of reactive oxygen species in LD [79], which may 
contribute to neuronal stress and apoptosis. These possibilities will be further discussed 
in the following section. 
An additional point relevant for the lysosomal alterations discussed here is that 
either malin or laforin could have independent functions of each other and in this 
regard, a specific malin function in the biogenesis and/or lysosomal glycogen disposal 
has been suggested [68]. However, the relevance of the specific loss of these functions, 
when one but not the other of the two proteins implicated in LD is defective, appears to 
be inconsistent with the observation that defects in malin or in laforin produce a quite 
similar phenotype in patients. Also, other alterations in the endocytic and lysosomal 
systems have been described in a laforin-deficient model of LD [80], which may or may 
not derive from the autophagic alterations.  
In summary, defects in both UPS and autophagy in LD have been extensively 
documented. Now, a critical question is whether the defects in the UPS and in 
autophagy described above are a cause or a consequence of the LD pathology [81]. In 
the case of autophagy, more recent data indicate that inhibition of glycogen synthesis 
prevents LD in mice [41] and that glycogen accumulation produces the impaired 
autophagy and not the opposite [28, 68]. Also, unpublished data from various 
laboratories have indicated that enhancing the activity of the autophagic pathway is not 
an appropriate therapeutic option in LD. Therefore, although on the basis of the recent 
available results the observed alterations in the UPS and autophagy may appear to be 
secondary to the accumulation of polyglucosans, probably because LBs recruit critical 
factors involved in the regulation of the UPS and autophagy, further details are needed. 
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Also, the relevance of these alterations in the protein homeostasis machinery should not 
be minimized and needs to be further investigated to reach more definitive conclusions. 
For example, even if the observed defects are secondary, it is important to identify the 
signalling mechanisms by which LBs impair the main proteolytic pathways in the cells. 
Also and since it is obvious that the above mentioned alterations will considerably 
worsen the pathology, it will be important to know how they contribute to the clinical 
phenotype. All these and other aspects related with the impairment in the main 
pathways of intracellular protein degradation in LD will be certainly addressed in 
various laboratories in the near future. 
 
4. Increased oxidative stress in Lafora disease 
The relationships between defects in the cellular proteolytic pathways and the 
generation of reactive oxygen species (ROS) have been broadly documented. 
Impairment in protein clearance systems imperatively leads to ER-stress, as described 
above, and the accumulation of misfolded proteins and dysfunctional protein aggregates 
which act as targets of basal ROS levels, give rise to oxidized protein products [82]. In 
normal cell conditions, this accumulation is rapidly surpassed by the ubiquitination and 
targeting to the proteasome of oxidized protein products and misfolded aggregates, in a 
chaperone and co-chaperone mediated manner [83], as discussed in the previous 
section. It is interesting, however, that ubiquitination-dependent and independent 
processes are involved in oxidized protein degradation by proteasomes, keeping in mind 
that large aggregates can inhibit the proteasome and that the process differs with the 
length and degree of the oxidative stress insult [82]. The elimination of protein 
oxidation products and misfolded aggregates is hence tightly linked to prolonged 
oxidative stress, affecting proteasome and chaperone-mediated protein clearance at 
different levels, highlighting the importance of maintaining a refined balance between 
ROS production and protein homeostasis, as reflected in the numerous evidences of 
neurodegenerative diseases in which one or both of these processes are affected [84, 
85]. 
A growing amount of evidence in recent years suggests that oxidative stress, via 
ROS and reactive nitrogen species (RNS), are key signal transducers sustaining 
autophagy [86]. Autophagy becomes the alternative solution to eliminate oxidized 
protein aggregates that overwhelm proteasomal activity. However, in a scenario of 
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proteolytic and/or autophagic impairment, as it is the case in LD (see previous section) 
[19, 51, 68, 81], these protein aggregates would accumulate. Antioxidant response 
elements provide a defensive shield against ROS by preventing the deleterious effect of 
protein oxidation and accumulation; hence, defective antioxidant systems worsen the 
previously described scenario, contributing to a positive, deleterious feedback. 
Autophagy also participates in the response against increased ROS levels: mitophagy, 
for example, is induced by oxidative stress, promoting the removal of dysfunctional 
mitochondria. In fact, in mitophagy-deficient cells, the excess of altered mitochondria 
leads to an overproduction of ROS [87]. In addition, ROS such as O2·
-
 and H2O2 induce 
autophagy, although experimental evidence has shown that this induction depends on 
stress conditions and cell type. ROS also regulate different proteins relevant in 
autophagy, such as mTOR, AMPK, Beclin-1, the pro-autophagy protein HMGB1, Atg4, 
and Atg8 (LC3 in mammals), among others [88, 89]. Furthermore, it has been shown 
that chemically induced oxidation of glutathione (GSH) is able to promote autophagy 
even in the absence of any autophagic stimulus [90].  
Thus, the proteolytic mechanisms represented by autophagy and proteasomal 
degradation are closely related to oxidative stress and cellular redox homeostasis, in 
both physiological and pathological conditions. This relationship is regulated by 
specific mediators, which play a pivotal role. Next, we will discuss the putative role of 
this particular kind of proteins in the development of LD, and the evidences of the 
involvement of antioxidant response impairment and/or an exacerbated ROS production 
in the ethiopathology of the disease. 
4.1. Linking proteasome defects to antioxidant response in LD 
One of the most important cellular sensors of oxidative stress are those proteins with 
enzymatic activity based in thiol reduction, including glutathione peroxidases (GPXs), 
thioredoxins (Trxs) and peroxiredoxins (Prdxs) [91, 92]. Proteins from these families 
act as regulators of disulfide bridge formation involved in reversible protein function 
activation, but they also participate in the elimination of abnormal disulfides produced 
by an unbalance in ROS production. In recent years, various evidences have 
demonstrated the linkage between some of these reducing agents and the proteolytic 
machinery of the cell: for instance, thioredoxin-1 (Trx1) and Txnl1/TRP32 
(thioredoxin-like protein1/thioredoxin-related protein of 32 kDa) interact both with 
misfolded proteins and proteasomal subunits [57, 93, 94]. In this line of evidence, we 
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described that Trx1 interacts with the 20S proteasome and translocates to the ER upon 
proteasome inhibition, producing an induction of the antioxidant response and an 
increase in ER-stress markers in human fibroblasts [57]. As discussed previously, the 
lack of laforin activity has been shown to correlate with impairment in proteasomal 
activity and ER-stress, both in siRNA-mediated gene silencing in culture cells and in 
specific tissues of laforin-deficient mice [51]. The fact that both ER-stress and 
proteasome activity is affected in LD cells and animal models, suggested that 
antioxidant defense systems are impaired. This was tested for the first time using 
fibroblasts from LD patients with mutations in the laforin gene, in which the 
impairment of proteasome activity paralleled a decrease in the levels of Trx1 [57]. 
Moreover, it was shown in this same study that LD fibroblasts exhibited a 
mislocalization of Trx1 and proteasomes, with diminished Trx1 and proteasome co-
localization in the nucleus. Since Trx1 migration to the nucleus has been related with an 
active antioxidant response, the mislocalization observed in LD fibroblasts, together 
with the proteolytic defects, strongly pointed to an abnormal antioxidant response in 
these cells [57]. 
4.2. Defective antioxidant enzymes in LD 
The data obtained in the study of Trx1 and its involvement in the proteasomal 
function of laforin-deficient cells [57] were further broadened by analyzing a series of 
antioxidant enzymes in both laforin- and malin-deficient cells from human patients and 
LD mice models [79]. Overall, this analysis showed a clear unbalance in the expression 
levels of concrete antioxidant enzymes, together with a significant decrease in their 
enzymatic activity. Particularly affected were cytosolic and mitochondrial superoxide 
dismutases (CuZnSOD and MnSOD, respectively), and catalase, whereas no apparent 
changes were observed for other antioxidant enzymes like glutathione peroxidases 
(GPXs) (Figure 3).  
Using LD mice models [79], we also showed that malin KO mice displayed an 
increment in lipid peroxides in plasma, which indicates a systemic chronic oxidative 
stress as a consequence of excessive ROS production. This increase in oxidative stress 
could explain why patients suffering from LD show increased levels of oxidative stress 
markers such as 8-hydroxy-2’-deoxyguanosine (8-OHdG) and 8-hydroxyguanosine (8-
OHG) (markers of DNA and RNA oxidative damage) in cerebral cortex and urine [95].  
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The examination of oxidative stress parameters in LD depicts a landscape in 
which antioxidant enzymes appear severely affected, as expected in cells with an altered 
proteolytic system and a defective response to misfolded proteins [44, 63, 96, 97] 
together with an increase in ER-stress. Interestingly, our proteomic analysis performed 
on brain extracts from malin-deficient mice [79] showed some differences in its protein 
content profile as compared to control mice. The most relevant data provided by this 
analysis refer to a protein belonging to the family of Prdxs, peroxiredoxin-6 (Prdx6), 
and a mitochondrial membrane channel, VDAC2 (voltage-dependent anion channel 2, 
which will be discussed in the next section). Malin-deficient mice showed no 
differences in the total levels of Prdx6, but an increment in a post-translationally 
modified form that remains, to date, uncertain. Some authors have suggested that acidic 
forms of Prdx6 correspond to oxidized forms, although several works demonstrated that 
the modifications of Prdx6 are multiple and variable, including, among others, different 
degrees of cysteine oxidation, acetylation and phosphorylation [98, 99]. Prdx6 
overexpression or post-translational modifications have been related to oxidative stress 
damage and proteolytic impairment in relation to several pathologies [100-105], 
including neurodegenerative disorders [106-108]. Prdx6 is particular among the rest of 
the peroxiredoxin family members, since it shows a bifunctional enzymatic activity both 
as glutathione peroxidase and as a phospholipase [109]. It has been proposed that the 
phospholipase activity of Prdx6 is related to autophagosome regulation, thus linking 
again oxidative stress responses with autophagy [110, 111]. Particularly interesting are 
recent results obtained by Yu and collaborators, in which Prdx6 hyperoxidation 
promotes its phospholipase activity, increasing cytotoxicity in astrocytes and 
contributing to neurodegeneration in a Parkinson disease mouse model [112].   
Taking together all the data on antioxidant enzyme alterations in LD, it seems that 
the most affected antioxidant defense systems are those involving enzymes that 
decrease superoxide levels in the cell (see Figure 3). However, the unanswered 
questions concern the main source of ROS overproduction and the precise chain of 
events that leads to the proteolytic and oxidative stress defense alterations in LD and to 
neurodegeneration. 
4.3. Mitochondrial dysfunction and ROS production: what came first?  
Mitochondria are one of the main sources of ROS in the cell, and mitochondrial 
homeostasis is tightly linked to autophagy [113]. Thus, an increase in morphologically 
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and functionally altered mitochondria could reflect a failure in the autophagic process. 
Indeed, mitochondria from both laforin- and malin-deficient fibroblasts from human 
patients display an abnormal morphology, decreased membrane potential and ATP 
production, and an increment in ROS levels, particularly superoxide production [79]. 
Our findings in LD fibroblasts demonstrate that mitochondria from laforin- and malin-
deficient cells have lost their normal morphology and appear aggregated, hence 
contributing to the loss of mitochondrial membrane potential and low efficiency of the 
mitochondrial transport chain [79]. These results seem to suggest that the origin of 
oxidative stress in LD could be found in the interplay between autophagy and 
mitochondrial function; however, the rest of defects on proteolytic systems and the 
related accumulation of aberrant glycogen granules and misfolded protein aggregates 
should also be taken into account, making difficult to assess which process constitutes 
the first failure that triggers a positive feedback that ultimately leads to cell malfunction 
(Figure 4).  
Besides an altered morphology and physiological function of mitochondria from 
laforin- and malin-deficient cells, the aforementioned proteomic analysis performed on 
brain extracts from malin KO mice [79] highlighted an increase in the levels of 
VDAC2. VDAC1 and VDAC2 are voltage dependent channels located in the outer 
mitochondrial membrane and tightly related to mitophagy [114]. The relationship 
between mitophagy defects and ROS overproduction has been already documented [87]. 
Although no physiological explanation for the increase in VDAC2 levels has been 
found, it is interesting that using similar proteomic approaches other groups have found 
alterations in VDAC2 expression in other types of epilepsy [115, 116]. 
As a summary, the interplay between autophagy impairment, mitochondrial 
dysfunction and overproduction of ROS, together with the incapacity in the cell’s 
response to oxidative stress (Figure 4 and Table 1), depicts a landscape that fits with the 
rest of disruptions reported in cell homeostasis in LD: ER-stress, proteasomal 
dysfunction and aberrant glycogen accumulation. The additive effect of these altered 
pathways ultimately leads neurons and other cell types in LD to dysfunction, and 
probably cell death. 
 
5. Concluding remarks and perspectives 
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5.1. Laforin, malin and redox-regulated signaling pathways 
As it has been explained above, laforin and malin are proteins with biochemically 
and functionally different features that form a functional complex, upon which several 
cellular processes of critical relevance for cell survival depend. In this review we 
introduce oxidative stress as a novel factor to be taken into consideration with the many 
other processes that we have discussed in the previous sections, which are regulated by, 
or directly linked to, the disruption of the laforin-malin complex. Noteworthy, little 
evidence pointed previously to a close linkage between redox regulation and laforin or 
malin. Some data, nonetheless, seem to favor this relationship. Degradation of 
misfolded proteins and ER stress are processes closely related to ROS overproduction, 
and hence the possibility that in the absence of laforin and/or malin the amount of 
oxidized proteins increases, is a plausible hypothesis.  
Since laforin is a dual specificity phosphatase whose activity is dependent on a 
cysteine residue, redox conditions are critical to determine its enzymatic activity. The 
regulation of phosphatase activity by reversible oxidation of catalytic cysteine residues 
has been broadly documented [117, 118], but still little is known about the enzymes 
involved in regulating these oxidation-reduction processes. Recent findings describe the 
participation of Trx1 and TRP32 in the reactivation of tyrosine phosphatases closely 
related to laforin [119, 120], providing interesting clues on the precise regulated redox 
signaling that open novel paths to examine laforin’s biochemical functions in relation to 
redox conditions in the cell. In addition, it has been found that laforin forms 
homodimers, being involved in this oligomerization a particular cysteine residue 
different from the one in the catalytic site. For this reason, laforin is prone to aggregate 
in the absence of a reducing environment [121, 122]. This indicates another layer of 
complexity in the regulation of laforin activity by oxidative conditions. 
In all, this evidence fits with the relevance of a correct oxidative stress response and 
a careful regulation of redox environment for the proper physiological function of the 
laforin-malin complex, although further data are needed to completely assess their fine 
regulation, and the identity of other pivotal antioxidant enzymes. 
5.2. Therapeutic potential of antioxidant treatments in LD 
Oxidative stress has been linked to a myriad of human diseases. Excessive free 
radicals have been described in aging, and in almost all major human diseases including 
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cancer, atherosclerosis, stroke, emphysema, and neurodegenerative diseases, such as 
Alzheimer’s disease and Parkinson’s disease. Neganova and collaborators proposed that 
free radicals may also contribute to brain damage, neuronal death and persistent seizures 
in epilepsy [123]. Interestingly, epilepsy increases NOSII gene expression through NF-
κB induction, with concomitant NO, O2
·-
, and ONOO dependent decrease of Complex I 
activity and increased Complex-III-dependent O2
·- 
production in epileptic brain 
mitochondria [124, 125]. Since oxidative stress is a relevant factor in some epilepsies, 
antioxidant intervention has been described in some of these pathologies. For example, 
the use of acetyl-l-carnitine has shown beneficial effects in epilepsy [125], an 
antioxidant therapy has been proposed as an anticonvulsive and neuroprotective 
treatment strategy against epilepsy [126] and the use of tryptamine (a serotonin receptor 
agonist and serotonin releasing agent), which is a derivative of securinine [a gamma-
aminobutyric acid (GABA) receptor antagonist], has been proposed as an antioxidant 
and anticonvulsant drug [123]. Consequently, and since oxidative stress dysfunction is 
present in LD, we suggest that the use of an antioxidant therapy as a therapeutic 
intervention in LD may be beneficial in the treatment of this terrible disease. 
In summary, since enhancing the activity of the autophagic pathway appears not 
to be an appropriate therapeutic option in LD, we propose that the findings on 
mitochondrial malfunction, ROS overproduction and antioxidant defense alterations in 
LD become a novel piece in the intricate puzzle of LD neurodegenerative process, and 
might provide interesting and currently uninvestigated ways to understand and fight the 
development of this devastating disease.  
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Figure legends 
Figure 1. Molecular pathways altered in LD. Glycogen metabolism (A) and 
misfolded protein response (B) are two cellular processes in which severe alterations in 
LD have been described, producing an unbalance in glycogen homeostasis and protein 
clearance. Recently, mitochondrial function has been proposed as another critical 
process altered in LD, producing an increase in ROS levels and contributing to 
worsening the cellular homeostasis. 
Figure 2. Implication of the major pathways of intracellular protein degradation in 
LD. The laforin-malin interaction facilitates the activity of malin as an E3-ubiquitin 
ligase that in coordination with still unknown E2-ubiquitin conjugating enzymes, 
promotes the ubiquitination of proteins involved in LD. A and B indicate alternative 
pathways in the degradation of these proteins, either by proteasomes (A) or by 
autophagy (B). Lysosomes degrade intracellular proteins by quite different mechanisms 
including microautophagy, chaperone mediated autophagy (CMA) and 
macroautophagy. The latter is by far the main lysosomal degradative route used under 
stress conditions, and includes elimination of dysfunctional mitochondria (mitophagy). 
Increased production of ROS affects the activity of proteasomes and also damages 
proteins and mitochondria that are in turn eliminated by the autophagic pathways (see 
text for details). (?) indicates possible degradative pathways implicated in LD but not 
yet tested.  
Figure 3. Oxidative stress parameters and antioxidant enzymes affected in LD. In 
normal conditions, an excessive superoxide production is counteracted by the action of 
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cytosolic (CuZnSOD) and mitochondrial (MnSOD) dismutases, which produce 
hydrogen peroxide. The levels of hydrogen peroxide can then be decreased by three 
main pathways, catalyzed by catalase, peroxiredoxins (PRDXs) or glutathione 
peroxidases (GPXs) that use glutathione as the reducing agent. In LD, increased levels 
of superoxide seem to be the main source of excessive ROS in LD human fibroblasts 
(LD-Fs), and alterations (either at the protein level or in enzymatic activity) have been 
found in superoxide dismutases and catalase (colored in red), either in LD-Fs or LD  
mice models (LD mice). Peroxiredoxin-6 (Prdx6) and thioredoxin-1 (Trx1) (colored in 
pink) are also oxidative stress-related proteins altered in LD mice or human fibroblasts 
at a functional level (see text for details). 
Figure 4. Interplay between oxidative stress and proteostasis in LD. Absence of 
laforin or malin, or defects in the function of the laforin-malin complex, have been 
independently related with defects in autophagy, proteasomal degradation, response to 
misfolded proteins and mitochondrial function. These processes interact with each 
other, contributing to the worsening of the loss of cellular homeostasis and probably 
also to the accumulation of LBs. 
Table 1. Summary of cellular and molecular alterations found in the different LD 
models. (See text for references and details). 
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